THE DEFINITIVE GUIDE TO TRASTUZUMAB DOSING

In July 2024, the CHMP adopted a beneficial feeling, recommending the granting of the advertising authorization for that medicinal product Tuznue, intended with the treatment of breast and gastric cancer.Discontinue trastuzumab treatment method in patients obtaining adjuvant therapy, and withhold trastuzumab in patients with metastatic disorder for